[GetPortalCommentsPageByObjectIdResponse(id=1053582, encodeId=dde41053582a7, content=投稿命中率:25.0<br>经验分享:撰写肿瘤分期,第三天显示under review,希望能顺利外审!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Tue Sep 21 21:56:26 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484932, encodeId=ff1f48493240, content=帮别人写了1篇,半年发表,自己投了1篇,半年才给个回复,莫名其妙!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=511, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Oct 18 16:29:00 CST 2011, time=2011-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555242, encodeId=bcfe5552426c, content=3月22号投稿 <br> 4月10号大修 <br> 4月21日修改完再次投稿 <br> 当日接收,效率最快的一次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=464, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02681608493, createdName=showen, createdTime=Sat Apr 21 19:05:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587456, encodeId=7fe358e456a1, content=亲,最后咋样了?<span class="quote">188****8186(暂无匿称) 2019-04-14 00:08:00 发表:<br>投稿1周内就送外审了UnderReview中希望顺利接受</span>, beContent=188****8186(暂无匿称) 2019-04-14 00:08:00 发表:
投稿1周内就送外审了UnderReview中希望顺利接受, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLvdkH0jmPBljZUbZvdObtFEh4XFq0Or5JXGXMx5S9qHU3r6ZnlicJiaMNqnFp5hVdnCMmnh9eC4R8Q/132, createdBy=746b5197351, createdName=钱湖鑫, createdTime=Thu Mar 26 00:00:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583438, encodeId=667b583438bc, content=cas升级版分区绿皮是一区top了。。。我喜欢。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Thu Jan 16 00:00:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579812, encodeId=58565e9812b4, content=绿皮好像换了主编,要开始拉if了?elsevier旗下的许多杂志if都开始猛涨了<span class="quote">188****8186(暂无匿称) 2019-11-01 00:00:00 发表:<br>Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?</span>, beContent=188****8186(暂无匿称) 2019-11-01 00:00:00 发表:
Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Wed Nov 13 00:00:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579154, encodeId=2c4c5e915402, content=Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?<span class="quote">188****8186(暂无匿称) 2019-09-28 00:00:00 发表:<br>我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天</span>, beContent=188****8186(暂无匿称) 2019-09-28 00:00:00 发表:
我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Fri Nov 01 00:00:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577044, encodeId=07675e7044b7, content=我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天<span class="quote">LLL123456789 2018-09-03 10:57:00 发表:<br>with editor 1个月,啥情况啊</span>, beContent=LLL123456789 2018-09-03 10:57:00 发表:
with editor 1个月,啥情况啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Sat Sep 28 00:00:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560670, encodeId=fc4e5606e048, content=with editor 1个月,啥情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4def2361633, createdName=LLL123456789, createdTime=Mon Sep 03 10:57:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560669, encodeId=03f25606691a, content=with editor 1个月,瑟瑟发抖....., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4def2361633, createdName=LLL123456789, createdTime=Mon Sep 03 10:56:00 CST 2018, time=2018-09-03, status=1, ipAttribution=)]
[GetPortalCommentsPageByObjectIdResponse(id=1053582, encodeId=dde41053582a7, content=投稿命中率:25.0<br>经验分享:撰写肿瘤分期,第三天显示under review,希望能顺利外审!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Tue Sep 21 21:56:26 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484932, encodeId=ff1f48493240, content=帮别人写了1篇,半年发表,自己投了1篇,半年才给个回复,莫名其妙!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=511, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Oct 18 16:29:00 CST 2011, time=2011-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555242, encodeId=bcfe5552426c, content=3月22号投稿 <br> 4月10号大修 <br> 4月21日修改完再次投稿 <br> 当日接收,效率最快的一次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=464, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02681608493, createdName=showen, createdTime=Sat Apr 21 19:05:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587456, encodeId=7fe358e456a1, content=亲,最后咋样了?<span class="quote">188****8186(暂无匿称) 2019-04-14 00:08:00 发表:<br>投稿1周内就送外审了UnderReview中希望顺利接受</span>, beContent=188****8186(暂无匿称) 2019-04-14 00:08:00 发表:
投稿1周内就送外审了UnderReview中希望顺利接受, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLvdkH0jmPBljZUbZvdObtFEh4XFq0Or5JXGXMx5S9qHU3r6ZnlicJiaMNqnFp5hVdnCMmnh9eC4R8Q/132, createdBy=746b5197351, createdName=钱湖鑫, createdTime=Thu Mar 26 00:00:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583438, encodeId=667b583438bc, content=cas升级版分区绿皮是一区top了。。。我喜欢。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Thu Jan 16 00:00:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579812, encodeId=58565e9812b4, content=绿皮好像换了主编,要开始拉if了?elsevier旗下的许多杂志if都开始猛涨了<span class="quote">188****8186(暂无匿称) 2019-11-01 00:00:00 发表:<br>Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?</span>, beContent=188****8186(暂无匿称) 2019-11-01 00:00:00 发表:
Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Wed Nov 13 00:00:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579154, encodeId=2c4c5e915402, content=Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?<span class="quote">188****8186(暂无匿称) 2019-09-28 00:00:00 发表:<br>我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天</span>, beContent=188****8186(暂无匿称) 2019-09-28 00:00:00 发表:
我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Fri Nov 01 00:00:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577044, encodeId=07675e7044b7, content=我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天<span class="quote">LLL123456789 2018-09-03 10:57:00 发表:<br>with editor 1个月,啥情况啊</span>, beContent=LLL123456789 2018-09-03 10:57:00 发表:
with editor 1个月,啥情况啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Sat Sep 28 00:00:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560670, encodeId=fc4e5606e048, content=with editor 1个月,啥情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4def2361633, createdName=LLL123456789, createdTime=Mon Sep 03 10:57:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560669, encodeId=03f25606691a, content=with editor 1个月,瑟瑟发抖....., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4def2361633, createdName=LLL123456789, createdTime=Mon Sep 03 10:56:00 CST 2018, time=2018-09-03, status=1, ipAttribution=)]
[GetPortalCommentsPageByObjectIdResponse(id=1053582, encodeId=dde41053582a7, content=投稿命中率:25.0<br>经验分享:撰写肿瘤分期,第三天显示under review,希望能顺利外审!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Tue Sep 21 21:56:26 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484932, encodeId=ff1f48493240, content=帮别人写了1篇,半年发表,自己投了1篇,半年才给个回复,莫名其妙!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=511, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Oct 18 16:29:00 CST 2011, time=2011-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555242, encodeId=bcfe5552426c, content=3月22号投稿 <br> 4月10号大修 <br> 4月21日修改完再次投稿 <br> 当日接收,效率最快的一次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=464, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02681608493, createdName=showen, createdTime=Sat Apr 21 19:05:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587456, encodeId=7fe358e456a1, content=亲,最后咋样了?<span class="quote">188****8186(暂无匿称) 2019-04-14 00:08:00 发表:<br>投稿1周内就送外审了UnderReview中希望顺利接受</span>, beContent=188****8186(暂无匿称) 2019-04-14 00:08:00 发表:
投稿1周内就送外审了UnderReview中希望顺利接受, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLvdkH0jmPBljZUbZvdObtFEh4XFq0Or5JXGXMx5S9qHU3r6ZnlicJiaMNqnFp5hVdnCMmnh9eC4R8Q/132, createdBy=746b5197351, createdName=钱湖鑫, createdTime=Thu Mar 26 00:00:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583438, encodeId=667b583438bc, content=cas升级版分区绿皮是一区top了。。。我喜欢。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Thu Jan 16 00:00:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579812, encodeId=58565e9812b4, content=绿皮好像换了主编,要开始拉if了?elsevier旗下的许多杂志if都开始猛涨了<span class="quote">188****8186(暂无匿称) 2019-11-01 00:00:00 发表:<br>Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?</span>, beContent=188****8186(暂无匿称) 2019-11-01 00:00:00 发表:
Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Wed Nov 13 00:00:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579154, encodeId=2c4c5e915402, content=Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?<span class="quote">188****8186(暂无匿称) 2019-09-28 00:00:00 发表:<br>我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天</span>, beContent=188****8186(暂无匿称) 2019-09-28 00:00:00 发表:
我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Fri Nov 01 00:00:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577044, encodeId=07675e7044b7, content=我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天<span class="quote">LLL123456789 2018-09-03 10:57:00 发表:<br>with editor 1个月,啥情况啊</span>, beContent=LLL123456789 2018-09-03 10:57:00 发表:
with editor 1个月,啥情况啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Sat Sep 28 00:00:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560670, encodeId=fc4e5606e048, content=with editor 1个月,啥情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4def2361633, createdName=LLL123456789, createdTime=Mon Sep 03 10:57:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560669, encodeId=03f25606691a, content=with editor 1个月,瑟瑟发抖....., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4def2361633, createdName=LLL123456789, createdTime=Mon Sep 03 10:56:00 CST 2018, time=2018-09-03, status=1, ipAttribution=)]
[GetPortalCommentsPageByObjectIdResponse(id=1053582, encodeId=dde41053582a7, content=投稿命中率:25.0<br>经验分享:撰写肿瘤分期,第三天显示under review,希望能顺利外审!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Tue Sep 21 21:56:26 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484932, encodeId=ff1f48493240, content=帮别人写了1篇,半年发表,自己投了1篇,半年才给个回复,莫名其妙!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=511, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Oct 18 16:29:00 CST 2011, time=2011-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555242, encodeId=bcfe5552426c, content=3月22号投稿 <br> 4月10号大修 <br> 4月21日修改完再次投稿 <br> 当日接收,效率最快的一次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=464, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02681608493, createdName=showen, createdTime=Sat Apr 21 19:05:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587456, encodeId=7fe358e456a1, content=亲,最后咋样了?<span class="quote">188****8186(暂无匿称) 2019-04-14 00:08:00 发表:<br>投稿1周内就送外审了UnderReview中希望顺利接受</span>, beContent=188****8186(暂无匿称) 2019-04-14 00:08:00 发表:
投稿1周内就送外审了UnderReview中希望顺利接受, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLvdkH0jmPBljZUbZvdObtFEh4XFq0Or5JXGXMx5S9qHU3r6ZnlicJiaMNqnFp5hVdnCMmnh9eC4R8Q/132, createdBy=746b5197351, createdName=钱湖鑫, createdTime=Thu Mar 26 00:00:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583438, encodeId=667b583438bc, content=cas升级版分区绿皮是一区top了。。。我喜欢。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Thu Jan 16 00:00:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579812, encodeId=58565e9812b4, content=绿皮好像换了主编,要开始拉if了?elsevier旗下的许多杂志if都开始猛涨了<span class="quote">188****8186(暂无匿称) 2019-11-01 00:00:00 发表:<br>Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?</span>, beContent=188****8186(暂无匿称) 2019-11-01 00:00:00 发表:
Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Wed Nov 13 00:00:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579154, encodeId=2c4c5e915402, content=Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?<span class="quote">188****8186(暂无匿称) 2019-09-28 00:00:00 发表:<br>我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天</span>, beContent=188****8186(暂无匿称) 2019-09-28 00:00:00 发表:
我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Fri Nov 01 00:00:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577044, encodeId=07675e7044b7, content=我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天<span class="quote">LLL123456789 2018-09-03 10:57:00 发表:<br>with editor 1个月,啥情况啊</span>, beContent=LLL123456789 2018-09-03 10:57:00 发表:
with editor 1个月,啥情况啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Sat Sep 28 00:00:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560670, encodeId=fc4e5606e048, content=with editor 1个月,啥情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4def2361633, createdName=LLL123456789, createdTime=Mon Sep 03 10:57:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560669, encodeId=03f25606691a, content=with editor 1个月,瑟瑟发抖....., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4def2361633, createdName=LLL123456789, createdTime=Mon Sep 03 10:56:00 CST 2018, time=2018-09-03, status=1, ipAttribution=)]
[GetPortalCommentsPageByObjectIdResponse(id=1053582, encodeId=dde41053582a7, content=投稿命中率:25.0<br>经验分享:撰写肿瘤分期,第三天显示under review,希望能顺利外审!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Tue Sep 21 21:56:26 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484932, encodeId=ff1f48493240, content=帮别人写了1篇,半年发表,自己投了1篇,半年才给个回复,莫名其妙!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=511, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Oct 18 16:29:00 CST 2011, time=2011-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555242, encodeId=bcfe5552426c, content=3月22号投稿 <br> 4月10号大修 <br> 4月21日修改完再次投稿 <br> 当日接收,效率最快的一次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=464, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02681608493, createdName=showen, createdTime=Sat Apr 21 19:05:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587456, encodeId=7fe358e456a1, content=亲,最后咋样了?<span class="quote">188****8186(暂无匿称) 2019-04-14 00:08:00 发表:<br>投稿1周内就送外审了UnderReview中希望顺利接受</span>, beContent=188****8186(暂无匿称) 2019-04-14 00:08:00 发表:
投稿1周内就送外审了UnderReview中希望顺利接受, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLvdkH0jmPBljZUbZvdObtFEh4XFq0Or5JXGXMx5S9qHU3r6ZnlicJiaMNqnFp5hVdnCMmnh9eC4R8Q/132, createdBy=746b5197351, createdName=钱湖鑫, createdTime=Thu Mar 26 00:00:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583438, encodeId=667b583438bc, content=cas升级版分区绿皮是一区top了。。。我喜欢。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Thu Jan 16 00:00:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579812, encodeId=58565e9812b4, content=绿皮好像换了主编,要开始拉if了?elsevier旗下的许多杂志if都开始猛涨了<span class="quote">188****8186(暂无匿称) 2019-11-01 00:00:00 发表:<br>Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?</span>, beContent=188****8186(暂无匿称) 2019-11-01 00:00:00 发表:
Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Wed Nov 13 00:00:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579154, encodeId=2c4c5e915402, content=Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?<span class="quote">188****8186(暂无匿称) 2019-09-28 00:00:00 发表:<br>我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天</span>, beContent=188****8186(暂无匿称) 2019-09-28 00:00:00 发表:
我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Fri Nov 01 00:00:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577044, encodeId=07675e7044b7, content=我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天<span class="quote">LLL123456789 2018-09-03 10:57:00 发表:<br>with editor 1个月,啥情况啊</span>, beContent=LLL123456789 2018-09-03 10:57:00 发表:
with editor 1个月,啥情况啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Sat Sep 28 00:00:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560670, encodeId=fc4e5606e048, content=with editor 1个月,啥情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4def2361633, createdName=LLL123456789, createdTime=Mon Sep 03 10:57:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560669, encodeId=03f25606691a, content=with editor 1个月,瑟瑟发抖....., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4def2361633, createdName=LLL123456789, createdTime=Mon Sep 03 10:56:00 CST 2018, time=2018-09-03, status=1, ipAttribution=)]
[GetPortalCommentsPageByObjectIdResponse(id=1053582, encodeId=dde41053582a7, content=投稿命中率:25.0<br>经验分享:撰写肿瘤分期,第三天显示under review,希望能顺利外审!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Tue Sep 21 21:56:26 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484932, encodeId=ff1f48493240, content=帮别人写了1篇,半年发表,自己投了1篇,半年才给个回复,莫名其妙!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=511, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Oct 18 16:29:00 CST 2011, time=2011-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555242, encodeId=bcfe5552426c, content=3月22号投稿 <br> 4月10号大修 <br> 4月21日修改完再次投稿 <br> 当日接收,效率最快的一次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=464, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02681608493, createdName=showen, createdTime=Sat Apr 21 19:05:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587456, encodeId=7fe358e456a1, content=亲,最后咋样了?<span class="quote">188****8186(暂无匿称) 2019-04-14 00:08:00 发表:<br>投稿1周内就送外审了UnderReview中希望顺利接受</span>, beContent=188****8186(暂无匿称) 2019-04-14 00:08:00 发表:
投稿1周内就送外审了UnderReview中希望顺利接受, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLvdkH0jmPBljZUbZvdObtFEh4XFq0Or5JXGXMx5S9qHU3r6ZnlicJiaMNqnFp5hVdnCMmnh9eC4R8Q/132, createdBy=746b5197351, createdName=钱湖鑫, createdTime=Thu Mar 26 00:00:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583438, encodeId=667b583438bc, content=cas升级版分区绿皮是一区top了。。。我喜欢。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Thu Jan 16 00:00:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579812, encodeId=58565e9812b4, content=绿皮好像换了主编,要开始拉if了?elsevier旗下的许多杂志if都开始猛涨了<span class="quote">188****8186(暂无匿称) 2019-11-01 00:00:00 发表:<br>Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?</span>, beContent=188****8186(暂无匿称) 2019-11-01 00:00:00 发表:
Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Wed Nov 13 00:00:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579154, encodeId=2c4c5e915402, content=Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?<span class="quote">188****8186(暂无匿称) 2019-09-28 00:00:00 发表:<br>我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天</span>, beContent=188****8186(暂无匿称) 2019-09-28 00:00:00 发表:
我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Fri Nov 01 00:00:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577044, encodeId=07675e7044b7, content=我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天<span class="quote">LLL123456789 2018-09-03 10:57:00 发表:<br>with editor 1个月,啥情况啊</span>, beContent=LLL123456789 2018-09-03 10:57:00 发表:
with editor 1个月,啥情况啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Sat Sep 28 00:00:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560670, encodeId=fc4e5606e048, content=with editor 1个月,啥情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4def2361633, createdName=LLL123456789, createdTime=Mon Sep 03 10:57:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560669, encodeId=03f25606691a, content=with editor 1个月,瑟瑟发抖....., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4def2361633, createdName=LLL123456789, createdTime=Mon Sep 03 10:56:00 CST 2018, time=2018-09-03, status=1, ipAttribution=)]
绿皮好像换了主编,要开始拉if了?elsevier旗下的许多杂志if都开始猛涨了188****8186(暂无匿称) 2019-11-01 00:00:00 发表: Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?
188****8186(暂无匿称) 2019-11-01 00:00:00 发表:
Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?
[GetPortalCommentsPageByObjectIdResponse(id=1053582, encodeId=dde41053582a7, content=投稿命中率:25.0<br>经验分享:撰写肿瘤分期,第三天显示under review,希望能顺利外审!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Tue Sep 21 21:56:26 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484932, encodeId=ff1f48493240, content=帮别人写了1篇,半年发表,自己投了1篇,半年才给个回复,莫名其妙!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=511, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Oct 18 16:29:00 CST 2011, time=2011-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555242, encodeId=bcfe5552426c, content=3月22号投稿 <br> 4月10号大修 <br> 4月21日修改完再次投稿 <br> 当日接收,效率最快的一次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=464, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02681608493, createdName=showen, createdTime=Sat Apr 21 19:05:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587456, encodeId=7fe358e456a1, content=亲,最后咋样了?<span class="quote">188****8186(暂无匿称) 2019-04-14 00:08:00 发表:<br>投稿1周内就送外审了UnderReview中希望顺利接受</span>, beContent=188****8186(暂无匿称) 2019-04-14 00:08:00 发表:
投稿1周内就送外审了UnderReview中希望顺利接受, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLvdkH0jmPBljZUbZvdObtFEh4XFq0Or5JXGXMx5S9qHU3r6ZnlicJiaMNqnFp5hVdnCMmnh9eC4R8Q/132, createdBy=746b5197351, createdName=钱湖鑫, createdTime=Thu Mar 26 00:00:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583438, encodeId=667b583438bc, content=cas升级版分区绿皮是一区top了。。。我喜欢。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Thu Jan 16 00:00:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579812, encodeId=58565e9812b4, content=绿皮好像换了主编,要开始拉if了?elsevier旗下的许多杂志if都开始猛涨了<span class="quote">188****8186(暂无匿称) 2019-11-01 00:00:00 发表:<br>Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?</span>, beContent=188****8186(暂无匿称) 2019-11-01 00:00:00 发表:
Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Wed Nov 13 00:00:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579154, encodeId=2c4c5e915402, content=Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?<span class="quote">188****8186(暂无匿称) 2019-09-28 00:00:00 发表:<br>我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天</span>, beContent=188****8186(暂无匿称) 2019-09-28 00:00:00 发表:
我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Fri Nov 01 00:00:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577044, encodeId=07675e7044b7, content=我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天<span class="quote">LLL123456789 2018-09-03 10:57:00 发表:<br>with editor 1个月,啥情况啊</span>, beContent=LLL123456789 2018-09-03 10:57:00 发表:
with editor 1个月,啥情况啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Sat Sep 28 00:00:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560670, encodeId=fc4e5606e048, content=with editor 1个月,啥情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4def2361633, createdName=LLL123456789, createdTime=Mon Sep 03 10:57:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560669, encodeId=03f25606691a, content=with editor 1个月,瑟瑟发抖....., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4def2361633, createdName=LLL123456789, createdTime=Mon Sep 03 10:56:00 CST 2018, time=2018-09-03, status=1, ipAttribution=)]
Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?188****8186(暂无匿称) 2019-09-28 00:00:00 发表: 我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天
[GetPortalCommentsPageByObjectIdResponse(id=1053582, encodeId=dde41053582a7, content=投稿命中率:25.0<br>经验分享:撰写肿瘤分期,第三天显示under review,希望能顺利外审!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Tue Sep 21 21:56:26 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484932, encodeId=ff1f48493240, content=帮别人写了1篇,半年发表,自己投了1篇,半年才给个回复,莫名其妙!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=511, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Oct 18 16:29:00 CST 2011, time=2011-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555242, encodeId=bcfe5552426c, content=3月22号投稿 <br> 4月10号大修 <br> 4月21日修改完再次投稿 <br> 当日接收,效率最快的一次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=464, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02681608493, createdName=showen, createdTime=Sat Apr 21 19:05:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587456, encodeId=7fe358e456a1, content=亲,最后咋样了?<span class="quote">188****8186(暂无匿称) 2019-04-14 00:08:00 发表:<br>投稿1周内就送外审了UnderReview中希望顺利接受</span>, beContent=188****8186(暂无匿称) 2019-04-14 00:08:00 发表:
投稿1周内就送外审了UnderReview中希望顺利接受, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLvdkH0jmPBljZUbZvdObtFEh4XFq0Or5JXGXMx5S9qHU3r6ZnlicJiaMNqnFp5hVdnCMmnh9eC4R8Q/132, createdBy=746b5197351, createdName=钱湖鑫, createdTime=Thu Mar 26 00:00:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583438, encodeId=667b583438bc, content=cas升级版分区绿皮是一区top了。。。我喜欢。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Thu Jan 16 00:00:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579812, encodeId=58565e9812b4, content=绿皮好像换了主编,要开始拉if了?elsevier旗下的许多杂志if都开始猛涨了<span class="quote">188****8186(暂无匿称) 2019-11-01 00:00:00 发表:<br>Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?</span>, beContent=188****8186(暂无匿称) 2019-11-01 00:00:00 发表:
Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Wed Nov 13 00:00:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579154, encodeId=2c4c5e915402, content=Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?<span class="quote">188****8186(暂无匿称) 2019-09-28 00:00:00 发表:<br>我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天</span>, beContent=188****8186(暂无匿称) 2019-09-28 00:00:00 发表:
我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Fri Nov 01 00:00:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577044, encodeId=07675e7044b7, content=我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天<span class="quote">LLL123456789 2018-09-03 10:57:00 发表:<br>with editor 1个月,啥情况啊</span>, beContent=LLL123456789 2018-09-03 10:57:00 发表:
with editor 1个月,啥情况啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Sat Sep 28 00:00:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560670, encodeId=fc4e5606e048, content=with editor 1个月,啥情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4def2361633, createdName=LLL123456789, createdTime=Mon Sep 03 10:57:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560669, encodeId=03f25606691a, content=with editor 1个月,瑟瑟发抖....., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4def2361633, createdName=LLL123456789, createdTime=Mon Sep 03 10:56:00 CST 2018, time=2018-09-03, status=1, ipAttribution=)]
[GetPortalCommentsPageByObjectIdResponse(id=1053582, encodeId=dde41053582a7, content=投稿命中率:25.0<br>经验分享:撰写肿瘤分期,第三天显示under review,希望能顺利外审!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Tue Sep 21 21:56:26 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484932, encodeId=ff1f48493240, content=帮别人写了1篇,半年发表,自己投了1篇,半年才给个回复,莫名其妙!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=511, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Oct 18 16:29:00 CST 2011, time=2011-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555242, encodeId=bcfe5552426c, content=3月22号投稿 <br> 4月10号大修 <br> 4月21日修改完再次投稿 <br> 当日接收,效率最快的一次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=464, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02681608493, createdName=showen, createdTime=Sat Apr 21 19:05:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587456, encodeId=7fe358e456a1, content=亲,最后咋样了?<span class="quote">188****8186(暂无匿称) 2019-04-14 00:08:00 发表:<br>投稿1周内就送外审了UnderReview中希望顺利接受</span>, beContent=188****8186(暂无匿称) 2019-04-14 00:08:00 发表:
投稿1周内就送外审了UnderReview中希望顺利接受, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLvdkH0jmPBljZUbZvdObtFEh4XFq0Or5JXGXMx5S9qHU3r6ZnlicJiaMNqnFp5hVdnCMmnh9eC4R8Q/132, createdBy=746b5197351, createdName=钱湖鑫, createdTime=Thu Mar 26 00:00:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583438, encodeId=667b583438bc, content=cas升级版分区绿皮是一区top了。。。我喜欢。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Thu Jan 16 00:00:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579812, encodeId=58565e9812b4, content=绿皮好像换了主编,要开始拉if了?elsevier旗下的许多杂志if都开始猛涨了<span class="quote">188****8186(暂无匿称) 2019-11-01 00:00:00 发表:<br>Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?</span>, beContent=188****8186(暂无匿称) 2019-11-01 00:00:00 发表:
Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Wed Nov 13 00:00:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579154, encodeId=2c4c5e915402, content=Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?<span class="quote">188****8186(暂无匿称) 2019-09-28 00:00:00 发表:<br>我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天</span>, beContent=188****8186(暂无匿称) 2019-09-28 00:00:00 发表:
我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Fri Nov 01 00:00:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577044, encodeId=07675e7044b7, content=我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天<span class="quote">LLL123456789 2018-09-03 10:57:00 发表:<br>with editor 1个月,啥情况啊</span>, beContent=LLL123456789 2018-09-03 10:57:00 发表:
with editor 1个月,啥情况啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Sat Sep 28 00:00:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560670, encodeId=fc4e5606e048, content=with editor 1个月,啥情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4def2361633, createdName=LLL123456789, createdTime=Mon Sep 03 10:57:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560669, encodeId=03f25606691a, content=with editor 1个月,瑟瑟发抖....., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4def2361633, createdName=LLL123456789, createdTime=Mon Sep 03 10:56:00 CST 2018, time=2018-09-03, status=1, ipAttribution=)]
[GetPortalCommentsPageByObjectIdResponse(id=1053582, encodeId=dde41053582a7, content=投稿命中率:25.0<br>经验分享:撰写肿瘤分期,第三天显示under review,希望能顺利外审!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Tue Sep 21 21:56:26 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=484932, encodeId=ff1f48493240, content=帮别人写了1篇,半年发表,自己投了1篇,半年才给个回复,莫名其妙!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=511, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=, createdTime=Tue Oct 18 16:29:00 CST 2011, time=2011-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=555242, encodeId=bcfe5552426c, content=3月22号投稿 <br> 4月10号大修 <br> 4月21日修改完再次投稿 <br> 当日接收,效率最快的一次投稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=464, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02681608493, createdName=showen, createdTime=Sat Apr 21 19:05:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587456, encodeId=7fe358e456a1, content=亲,最后咋样了?<span class="quote">188****8186(暂无匿称) 2019-04-14 00:08:00 发表:<br>投稿1周内就送外审了UnderReview中希望顺利接受</span>, beContent=188****8186(暂无匿称) 2019-04-14 00:08:00 发表:
投稿1周内就送外审了UnderReview中希望顺利接受, objectType=tool_impact_factor, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLvdkH0jmPBljZUbZvdObtFEh4XFq0Or5JXGXMx5S9qHU3r6ZnlicJiaMNqnFp5hVdnCMmnh9eC4R8Q/132, createdBy=746b5197351, createdName=钱湖鑫, createdTime=Thu Mar 26 00:00:00 CST 2020, time=2020-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=583438, encodeId=667b583438bc, content=cas升级版分区绿皮是一区top了。。。我喜欢。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Thu Jan 16 00:00:00 CST 2020, time=2020-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579812, encodeId=58565e9812b4, content=绿皮好像换了主编,要开始拉if了?elsevier旗下的许多杂志if都开始猛涨了<span class="quote">188****8186(暂无匿称) 2019-11-01 00:00:00 发表:<br>Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?</span>, beContent=188****8186(暂无匿称) 2019-11-01 00:00:00 发表:
Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?, objectType=tool_impact_factor, channel=null, level=null, likeNumber=186, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Wed Nov 13 00:00:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=579154, encodeId=2c4c5e915402, content=Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:?
"What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).?
"Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)?
Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?<span class="quote">188****8186(暂无匿称) 2019-09-28 00:00:00 发表:<br>我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天</span>, beContent=188****8186(暂无匿称) 2019-09-28 00:00:00 发表:
我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天, objectType=tool_impact_factor, channel=null, level=null, likeNumber=196, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Fri Nov 01 00:00:00 CST 2019, time=2019-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577044, encodeId=07675e7044b7, content=我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天<span class="quote">LLL123456789 2018-09-03 10:57:00 发表:<br>with editor 1个月,啥情况啊</span>, beContent=LLL123456789 2018-09-03 10:57:00 发表:
with editor 1个月,啥情况啊, objectType=tool_impact_factor, channel=null, level=null, likeNumber=193, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Sat Sep 28 00:00:00 CST 2019, time=2019-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560670, encodeId=fc4e5606e048, content=with editor 1个月,啥情况啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=242, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4def2361633, createdName=LLL123456789, createdTime=Mon Sep 03 10:57:00 CST 2018, time=2018-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560669, encodeId=03f25606691a, content=with editor 1个月,瑟瑟发抖....., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4def2361633, createdName=LLL123456789, createdTime=Mon Sep 03 10:56:00 CST 2018, time=2018-09-03, status=1, ipAttribution=)]
投稿命中率:25.0
经验分享:撰写肿瘤分期,第三天显示under review,希望能顺利外审!
71
帮别人写了1篇,半年发表,自己投了1篇,半年才给个回复,莫名其妙!
511
3月22号投稿
4月10号大修
4月21日修改完再次投稿
当日接收,效率最快的一次投稿
464
亲,最后咋样了?188****8186(暂无匿称) 2019-04-14 00:08:00 发表:
投稿1周内就送外审了UnderReview中希望顺利接受
188****8186(暂无匿称) 2019-04-14 00:08:00 发表: 投稿1周内就送外审了UnderReview中希望顺利接受
191
cas升级版分区绿皮是一区top了。。。我喜欢。。。
184
绿皮好像换了主编,要开始拉if了?elsevier旗下的许多杂志if都开始猛涨了188****8186(暂无匿称) 2019-11-01 00:00:00 发表:
Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:? "What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).? "Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)? Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?
188****8186(暂无匿称) 2019-11-01 00:00:00 发表: Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:? "What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).? "Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)? Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?
186
Your manuscript has been reviewed by the Editors of the journal. Overall, it did not receive a high enough priority score for publication in the journal and will not proceed to peer-review. We currently have a very high number of excellent submissions and can publish only the very best papers. For further information please refer to our editorials:? "What next" (Radiother. Oncol. 2014 Jan; 110 (1): 1-2, ?https://www.sciencedirect.com/science/article/pii/S0167814014000450).? "Continuously getting a bit more picky…" (Radiother. Oncol. 2019 Jan; 130: 1,?https://www.sciencedirect.com/science/article/pii/S0167814018336491)? Thank you for giving us the opportunity to consider your work for publication in Radiotherapy & Oncology. ?Although your submission was not successful on this occasion, we hope that you will consider the journal for future work of relevance and importance to radiation oncology.?188****8186(暂无匿称) 2019-09-28 00:00:00 发表:
我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天
188****8186(暂无匿称) 2019-09-28 00:00:00 发表: 我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天
196
我最近也with editor20+天,你那篇最后怎么样?和我以前的投稿不一样,以前7-10天LLL123456789 2018-09-03 10:57:00 发表:
with editor 1个月,啥情况啊
LLL123456789 2018-09-03 10:57:00 发表: with editor 1个月,啥情况啊
193
with editor 1个月,啥情况啊
242
with editor 1个月,瑟瑟发抖.....
164